These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
138 related articles for article (PubMed ID: 17766663)
21. [Erythropoiesis-stimulating agents: favorable safety profile when used as indicated]. Adam M Strahlenther Onkol; 2008 Sep; 184(9):490. PubMed ID: 19016030 [No Abstract] [Full Text] [Related]
23. Erythropoiesis-stimulating agents in the treatment of cancer-associated anemia. Bohlius J; Engert A; Schwarzer G JAMA; 2008 Dec; 300(24):2854-5; author reply 2855-7. PubMed ID: 19109112 [No Abstract] [Full Text] [Related]
24. Thrombocytosis and venous thromboembolism in cancer patients with chemotherapy induced anemia may be related to ESA induced iron restricted erythropoiesis and reversed by administration of IV iron. Henry DH; Dahl NV; Auerbach MA Am J Hematol; 2012 Mar; 87(3):308-10. PubMed ID: 22262486 [TBL] [Abstract][Full Text] [Related]
25. Adverse consequences with use of erythropoiesis-stimulating agents in anemia prompt release of guidelines to ensure safe use and maximize benefit. Dharmarajan TS; Widjaja D Geriatrics; 2008 Jun; 63(6):13-29. PubMed ID: 18512996 [TBL] [Abstract][Full Text] [Related]
26. Managing Chemotherapy-Induced Anemia with Erythropoiesis-Stimulating Agents Plus Iron. Whitehead L Am J Nurs; 2017 May; 117(5):67. PubMed ID: 28448368 [TBL] [Abstract][Full Text] [Related]
30. The TREAT study answers a question, not the question. Coyne DW Am J Kidney Dis; 2008 Sep; 52(3):626-7; author reply 627-8. PubMed ID: 18725019 [No Abstract] [Full Text] [Related]
31. Correcting anemia in heart failure: the efficacy and safety of erythropoiesis-stimulating agents. Lawler PR; Filion KB; Eisenberg MJ J Card Fail; 2010 Aug; 16(8):649-58. PubMed ID: 20670844 [TBL] [Abstract][Full Text] [Related]
33. Economic evaluation of erythropoiesis-stimulating agents for anemia related to cancer. Klarenbach S; Manns B; Reiman T; Reaume MN; Lee H; Lloyd A; Wiebe N; Hemmelgarn B; Tonelli M Cancer; 2010 Jul; 116(13):3224-32. PubMed ID: 20564645 [TBL] [Abstract][Full Text] [Related]
34. Erythropoiesis-stimulating agents in anemia: use and misuse. Dharmarajan TS; Widjaja D J Am Med Dir Assoc; 2009 Nov; 10(9):607-16. PubMed ID: 19883882 [TBL] [Abstract][Full Text] [Related]
35. Choice of erythropoiesis stimulating agent in ESRD. Fishbane S; Shah HH Nephrol News Issues; 2013 Jun; 27(7):Supp 10-2. PubMed ID: 23855143 [No Abstract] [Full Text] [Related]
36. Treatment with erythropoiesis-stimulating agents in chronic kidney disease patients with cancer. Hazzan AD; Shah HH; Hong S; Sakhiya V; Wanchoo R; Fishbane S Kidney Int; 2014 Jul; 86(1):34-9. PubMed ID: 24402094 [TBL] [Abstract][Full Text] [Related]
37. Erythropoietic-stimulating agents: the cancer progression controversy and collateral damage to the blood supply. Adamson JW Transfusion; 2009 May; 49(5):824-6. PubMed ID: 19426200 [No Abstract] [Full Text] [Related]
38. Novel Masters of Erythropoiesis: Hypoxia Inducible Factors and Recent Advances in Anemia of Renal Disease. Solak Y; Cetiner M; Siriopol D; Tarim K; Afsar B; Covic A; Kanbay M Blood Purif; 2016; 42(2):160-7. PubMed ID: 27318465 [TBL] [Abstract][Full Text] [Related]
39. Intolerability of cobalt salt as erythropoietic agent. Ebert B; Jelkmann W Drug Test Anal; 2014 Mar; 6(3):185-9. PubMed ID: 24039233 [TBL] [Abstract][Full Text] [Related]